SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-027409
Filing Date
2022-10-31
Accepted
2022-10-31 16:04:19
Documents
12
Period of Report
2022-10-26
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K nltx-20221026.htm   iXBRL 8-K 31582
  Complete submission text file 0001628280-22-027409.txt   167179

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nltx-20221026.xsd EX-101.SCH 1962
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nltx-20221026_lab.xml EX-101.LAB 24137
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nltx-20221026_pre.xml EX-101.PRE 12569
6 EXTRACTED XBRL INSTANCE DOCUMENT nltx-20221026_htm.xml XML 10578
Mailing Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102
Business Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102 206-732-2133
Neoleukin Therapeutics, Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 221345981
SIC: 2834 Pharmaceutical Preparations